← Leaderboards
Jianjun Gao
University Of Tx Md Anderson Can Ctr
$3,992,332
Attributed
$5,958,423
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,958,423 · 3
By mechanism
R01$5,958,423 · 3
Top collaborators
- Nagireddy Putluri3 shared
- Mohummad Minhaj Siddiqui3 shared
- Liuqing Yang3 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Liuqing Yang$6,260,577
Others in their field
Other Emerging Leaders on “Tumor-Immune System Interactions”
- Kevin L. Gardner · Columbia University Health Sciences$5,786,729
- Gareth John Morgan · Tezcat Laboratories Llc$5,575,548
- Giedre Krenciute · St. Jude Children'S Research Hospital$4,209,927
- Samuel F Bakhoum · Weill Medical Coll Of Cornell Univ$4,035,467
- Cecilia Larocca · Brigham And Women'S Hospital$3,995,479
- J. Silvio Gutkind · University Of California, San Diego$3,943,862
Research focus
Tumor-Immune System InteractionsTumor-Infiltrating Immune CellsTumorMetabolicMediatingMalignant Neoplasm Of Urinary BladderMalignant NeoplasmsTissuesResponsePathway InteractionsMolecularImmunotherapyCheckpoint TherapySignal TransductionIn VivoCancer ModelInhibitorNeoplastic CellCancer CellCellsKnock-DownResistanceInterferonsImmunologics
Grant awards (11)
Decoding tumor metabolic and immunologic interactions driving different biological subtypes in patients with bladder cancer.$615,400
R01 · FY2025 · CA
Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment$535,778
R01 · FY2025 · CA · contact PI
Molecular Mechanisms of Bladder Cancer Immunometabolism$493,870
R01 · FY2025 · CA
Decoding tumor metabolic and immunologic interactions driving racial disparity in African American patients with bladder cancer.$584,631
R01 · FY2024 · CA
Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment$508,990
R01 · FY2024 · CA · contact PI
Molecular Mechanisms of Bladder Cancer Immunometabolism$468,881
R01 · FY2024 · CA
Decoding tumor metabolic and immunologic interactions driving racial disparity in African American patients with bladder cancer.$645,401
R01 · FY2023 · CA
Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment$525,061
R01 · FY2023 · CA · contact PI
Molecular Mechanisms of Bladder Cancer Immunometabolism$508,855
R01 · FY2023 · CA
Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment$535,778
R01 · FY2022 · CA · contact PI
Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment$535,778
R01 · FY2021 · CA · contact PI